GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Shares Outstanding (EOP)

Alliance Pharma (LSE:APH) Shares Outstanding (EOP) : 540.6 Mil (As of Jun. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Alliance Pharma's shares outstanding for the quarter that ended in Jun. 2024 was 540.6 Mil.

Alliance Pharma's quarterly shares outstanding increased from Dec. 2023 (540.4 Mil) to Jun. 2024 (540.6 Mil). It means Alliance Pharma issued new shares from Dec. 2023 to Jun. 2024 .

Alliance Pharma's annual shares outstanding increased from Dec. 2022 (540.0 Mil) to Dec. 2023 (540.4 Mil). It means Alliance Pharma issued new shares from Dec. 2022 to Dec. 2023 .


Alliance Pharma Shares Outstanding (EOP) Historical Data

The historical data trend for Alliance Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Shares Outstanding (EOP) Chart

Alliance Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 529.40 532.92 538.23 540.00 540.39

Alliance Pharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 539.74 540.00 540.15 540.39 540.57

Competitive Comparison of Alliance Pharma's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alliance Pharma's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Shares Outstanding (EOP) falls into.



Alliance Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Alliance Pharma  (LSE:APH) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Alliance Pharma Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma Business Description

Traded in Other Exchanges
N/A
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. The company generates the majority of its revenue from the Consumer Healthcare segment. The products of the company include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, Fazol, and others. Geographically, the company derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).